Table 4 Risk of all-causes mortality stratified by follow-up time of breast cancer survivors across tertiles of post-diagnosis E-DII from food plus supplement in the PLCO Cancer Screening Trial.

From: Long-term anti-inflammatory diet in relation to improved breast cancer prognosis: a prospective cohort study

 

E-DII tertile 1 (−7.8, −5.6)

E-DII tertile 2 (−5.6, −4.1)

E-DII tertile 3 (−4.1, 4.9)

Ptrend

Pinteractiona

≤15 person-years, (n)

180

172

216

 

<0.001

Death from any cause (n)

70

79

93

 

Age and energy-adjusted HR (95% CI)

1.00 (reference)

1.19 [0.87, 1.65]

1.27 [0.93, 1.73]

0.14

Multivariable-adjusted HR (95% CI)b

1.00 (reference)

1.21 [0.87, 1.69]

1.25 [0.91, 1.72]

0.18

>15 person-years (n)

175

182

139

 

Death from any cause (n)

16

19

19

 

Age and energy-adjusted HR (95% CI)

1.00 (reference)

1.29 [0.66, 2.52]

2.06 [1.05, 4.05]

0.04

Multivariable-adjusted HR (95% CI)b

1.00 (reference)

1.24 [0.61, 2.54]

2.18 [1.03, 4.64]

0.04

  1. aPinteraction was calculated by adding the cross-product of quartile E-DII and the follow-up time (≤15 person years and >15 person-years) in the COX proportional hazards regression model.
  2. bStratified by age of breast cancer diagnosis (≤60 years old, >60 years old), years from breast cancer diagnosis to DHQ completion (≤1 year, >1 year), stage (0/I, II/III) due to PH assumption violation and adjusted for total energy intake (continues, kcal/day), body mass index (continues, kg/m2), trial arm (control, intervention), race (white, black, others), marital status (single, married, divorced or separated, widowed), income(<$20,000, $20,000–$49,000, $50,000–$99,000, $100,000–$200,000, <$200,000), educational level (less than high school, high school graduate or equivalent, post-high school education, college education or higher), smoking status (never smoked, past smoked, current smoked), hormone replacement therapy (never used, former used, current used), history of diabetes (no, yes), physical activity (active less than one time per month, active at least one time per month), estrogen receptor status (negative, positive), and progesterone receptor status (negative, positive).